2024-02-15 16:10:07 ET
More on Pacific Biosciences of California
- Why Is Pacific Biosciences' Price Action So Bad? (Downgrade)
- Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth
- Pacific Biosciences' Revio And Onso Lead Looks Priced In For Now
- Pacific Biosciences of California Q4 2023 Earnings Preview
- Cantor picks RCEL as best 2024 medtech idea; bullish on PACB, AXGN, CERS
Read the full article on Seeking Alpha
For further details see:
Pacific Biosciences of California Non-GAAP EPS of -$0.27 beats by $0.01, revenue of $58.36M in-line